Blood-pressure-lowering peptide (PGPIHN)
A small natural peptide that blocks ACE, the enzyme that raises blood pressure, helping to lower it; studied as a potential treatment but not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Literature-extracted sequence peptide — synthesized for bioassay as documented in linked reference(s)
Fork this card to add platform evidence →
Activity measured in linked reference(s) — IC50/MIC/cytotoxicity data
Fork this card to add platform evidence →
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Can a single peptide lower blood pressure without disrupting the body's own heart-protective system?
Most ACE-inhibitor drugs block two related enzymes at once, which can blunt the body's own cardiovascular defenses. If PGPIHN turns out to be selective for only the harmful enzyme, it could offer blood pressure control with a cleaner safety profile, potentially relevant to people managing both hypertension and post-COVID heart stress.
Does this peptide do double duty against blood pressure, the way a leading prescription heart drug does?
A top-selling heart drug (Entresto) works by blocking two enzymes simultaneously. If PGPIHN does the same thing naturally, it could explain why food peptides sometimes lower blood pressure more than expected, and might point toward a safer, food-derived alternative worth developing further.
Could a single chemical change stop this peptide from being broken down before it reaches the bloodstream?
Most peptide medicines have to be injected because stomach enzymes destroy them before they absorb. If replacing one building block with a mirror-image version protects PGPIHN from digestion without killing its activity, that could open a path to an inexpensive oral pill rather than an injection, with minimal modifications to a naturally occurring molecule.
Is the way this peptide folds physically responsible for how well it blocks the blood pressure enzyme?
If a specific three-amino-acid shape turns out to be the key to ACE inhibition, researchers could use that blueprint to predict which proteins in common foods might yield similarly potent peptides when digested, speeding up the search for natural blood pressure ingredients.
Does this peptide from milk protein still work after your gut is done with it?
The biggest unsolved problem for food-based blood pressure peptides is whether they survive the journey from your mouth to your arteries. If PGPIHN passes that test at a reasonable dose in an animal model, it could qualify for development as a nutraceutical ingredient or functional food, offering a dietary option alongside or before medication for people with mildly elevated blood pressure.
Does one specific building block in this peptide do most of the work of blocking the enzyme?
If histidine at position five turns out to be the critical contact point with the enzyme's zinc core, chemists could swap it for stronger zinc-grabbing groups to build more potent, precisely targeted analogues, while keeping the rest of the natural peptide scaffold intact. That would turn a modest food-derived compound into a rational starting point for a new class of blood pressure drugs.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.7928875684738159 | boltz-2 |
| ranking score | 0.8742464184761047 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 1.090 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep04848,
sequence = {PGPIHN},
target = {ace},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}